SCHEMBL13879547

SCHEMBL13879547

COc1cccc(N2C(=O)NC(Cc3c[nH]c4ccccc34)C2=O)c1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.83
NPSR1 Q6W5P4 1/20 0.68
KMT2A Q03164 5/20 0.55
MAPT P10636 4/20 0.55
MEN1 O00255 3/20 0.55
LMNA P02545 3/20 0.55
USP2 O75604 1/20 0.55
HTT P42858 1/20 0.55
SMN1; SMN2 Q16637 2/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
IDO1 P14902 2/20 0.54
TP53 P04637 1/20 0.54
GLA P06280 1/20 0.54
CYP3A4 P08684 1/20 0.54
THRB P10828 1/20 0.54
RIPK1 Q13546 1/20 0.54
HSD17B10 Q99714 1/20 0.54
POLB P06746 3/20 0.53
PKM P14618 1/20 0.51
RAB9A P51151 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13879523 0.89 NPSR1 (0.80) GAANPSR1KMT2AMAPTMEN1
SCHEMBL13879470 0.86 NPSR1 (0.62) GAANPSR1KMT2AMAPTMEN1
SCHEMBL11639246 0.85 NPSR1 (0.73) GAANPSR1KMT2AMAPTMEN1
SCHEMBL13879424 0.81 NPSR1 (0.65) GAANPSR1KMT2AMAPTMEN1
SCHEMBL13879541 0.81 NPSR1 (0.61) GAANPSR1KMT2AMAPTMEN1
SCHEMBL13879430 0.79 NPSR1 (0.71) GAANPSR1KMT2AMAPTMEN1
SCHEMBL837717 0.75 RIPK1 (0.79) NPSR1KMT2AMAPTMEN1LMNA
SCHEMBL876699 0.75 RIPK1 (0.79) NPSR1KMT2AMAPTMEN1LMNA
SCHEMBL29764703 0.75 RIPK1 (0.79) NPSR1KMT2AMAPTMEN1LMNA
SCHEMBL877381 0.75 RIPK1 (0.79) NPSR1KMT2AMAPTMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION EIF2AK2, HAVCR2, RTF2 GAA 463/4885NPSR1 4621/4885KMT2A 2463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.